#REGOMUNE - a phase II #ClinicalTrial of #Regorafenib + #Avelumab in advanced 'cold' #SoftTissueSarcoma—shows that anti-angiogenic therapy modulates the #TumorMicroenvironment and boosts immune-mediated tumor destruction. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

This study evaluates the clinical efficacy of #regorafenib in combination with #avelumab in mTLS-negative #SoftTissueSarcoma patients, highlighting the potential of #antiangiogenic agents to modify the #TumorMicroEnvironment. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

Vaximm AG Unveils Promising Results from Their Phase 2a Trial of Innovative Glioblastoma Therapy Vaximm AG announced successful Phase 2a trial results, revealing the safety and potential efficacy of VXM01 combined with Avelumab for glioblastoma treatment.

Vaximm AG Unveils Promising Results from Their Phase 2a Trial of Innovative Glioblastoma Therapy #Switzerland #Basel #VXM01 #Avelumab #Vaximm_AG

Toni Choueiri: The Final Analysis of the JAVELIN Renal 101 trial - OncoDaily Toni Choueiri: The Final Analysis of the JAVELIN Renal 101 trial / Avelumab, axitinib, cancer, ESMO Annals of Oncology, Javelin Renal 101 trial, OncoDaily,

The Final Analysis of the JAVELIN Renal 101 trial - Toni Choueiri
@drchoueiri.bsky.social

oncodaily.com/science/210096

#Avelumab #Axitinib #Cancer #ESMO #JavelinRenal #Medicine #OncoDaily #Oncology #Sunitinib #Health